Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.

Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.

Oral tofacitinib successfully treated a girl's severe skin and hair conditions.

PDRN is effective and safe for healing wounds and skin issues.

The combined treatment helped prevent hair loss and promoted full hair regrowth in breast cancer patients after chemotherapy.

Cepharanthine shows promise as a natural anticancer treatment.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

Pro-Ile could be used in cosmetics to improve skin, hair growth, and healing.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

MK-5108 is safe and shows potential against tumors, especially alone.

Baricitinib significantly regrows hair in severe alopecia areata patients.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

Gefitinib treatment led to unexpected hair growth in two lung cancer patients.

Newly designed proteins can effectively degrade specific proteins in cells, offering a potential new therapy method.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

Topical IKKα inhibitors may help prevent CCS tumours.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

IGFBP-rP1 could be a new treatment for a common type of hair loss.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

KRT80 may worsen cancer by increasing growth and spread, but its full effects on treatment and outcomes need more research.